Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 23, 2024
Event Date: October 23, 2024 (Agreement); October 24, 2024 (Closing)
Context: The Company, an emerging growth company, entered into a Securities Purchase Agreement to conduct a registered direct offering and a concurrent private placement of warrants.
Key Financial Metrics and Transaction Details
This filing reports a capital raise event rather than periodic financial performance. Key metrics include:
- Gross Proceeds: Approximately $2,050,000 (before fees and expenses).
- Securities Issued:
- 2,050,000 shares of Common Stock at $1.00 per share.
- Series E Common Warrants: 2,050,000 shares, exercise price $1.13, exercisable after 6 months, 1-year term.
- Series F Common Warrants: 2,050,000 shares, exercise price $1.13, exercisable after 6 months, 5-year term.
- Placement Agent Warrants: 102,500 shares, exercise price $1.25, exercisable after 6 months, 5-year term.
- Placement Agent Fees: 8.0% cash fee, 1% management fee, plus reimbursement of out-of-pocket expenses.
- Placement Agent Warrant: 5% of the aggregate number of shares sold in the registered direct offering.
Material Changes and Agreements
The primary material change is the execution of the Securities Purchase Agreement and Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. Key contractual terms include:
- Market Stand-Off: The Company agreed not to issue Common Stock or equivalents for 30 days following closing.
- Variable Rate Transaction Prohibition: Prohibited for 6 months following closing, with specific exceptions for at-the-market offerings expiring on the six-month anniversary.
- Lock-Up Agreements:
- Company: 30-day lock-up.
- Directors and Executive Officers: 90-day lock-up.
- Registration Rights: The Company agreed to file a registration statement for the resale of warrant shares within 45 days of the Purchase Agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing does not contain forward-looking guidance, revenue projections, or specific management commentary regarding future operational milestones beyond the transaction details.
Risks and Contingencies:
- Dilution: The issuance of 2,050,000 shares and warrants covering an additional 4,100,000 shares (plus placement agent warrants) represents potential dilution to existing shareholders.
- Liquidity: The proceeds are intended to fund operations, though specific allocation is not detailed in this text.
- Unregistered Securities: The warrants were issued in reliance on Section 4(a)(2) and Regulation D exemptions and are not registered under the Securities Act until the resale registration statement is filed.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 9% total placement agent fees and other offering expenses.
- Confirm the effective date of the resale registration statement for the warrant shares (required within 45 days of Oct 23, 2024).
- Review the Company's cash runway and burn rate in the most recent 10-Q or 10-K to assess the sufficiency of the $2.05 million gross raise.
- Monitor compliance with the 30-day market stand-off and 90-day insider lock-up periods.
- Check for any subsequent filings regarding the exercise of warrants or additional capital raises.